A Retrospective Genomic Landscape of 661 Young Adult Glioblastomas Diagnosed Using 2016 WHO Guidelines for Central Nervous System Tumors

Author:

Haberberger James F1ORCID,Pegram Worthy1,Britt Nicholas1,Schiavone Kelsie1,Severson Eric1,Sharaf Radwa2ORCID,Albacker Lee A2,Williams Erik2,Lechpammer Mirna1,Hemmerich Amanda1,Lin Douglas1,Huang Richard S P1,Hiemenz Matthew2,Elvin Julia2,Graf Ryon2,Lesser Glenn3,Kram David3,Strowd Roy3,Bi Wenya Linda4ORCID,Ramkissoon Lori A5,Cohen Michael B6,Reddy Prasanth2,Creeden James2,Ross Jeffrey S27,Alexander Brian M2,Ramkissoon Shakti H16

Affiliation:

1. Pathology Department, Foundation Medicine , Morrisville, NC , USA

2. Pathology Department, Foundation Medicine , Cambridge, MA , USA

3. Pathology Department, Section on Hematology-Oncology, Wake Forest School of Medicine , Winston Salem, NC , USA

4. Department of Neurosurgery, Brigham and Women’s Hospital , Boston, MA , USA

5. Pathology Department, University of North Carolina School of Medicine , Chapel Hill, NC , USA

6. Wake Forest Comprehensive Cancer Center and Department of Pathology, Wake Forest School of Medicine , Winston-Salem, NC , USA

7. Pathology Department, SUNY Upstate Medical University , Syracuse, NY , USA

Abstract

Abstract The authors present a cohort of 661 young adult glioblastomas diagnosed using 2016 WHO World Health Organization Classification of Tumors of the Central Nervous System, utilizing comprehensive genomic profiling (CGP) to explore their genomic landscape and assess their relationship to currently defined disease entities. This analysis explored variants with evidence of pathogenic function, common copy number variants (CNVs), and several novel fusion events not described in literature. Tumor mutational burden (TMB) mutational signatures, anatomic location, and tumor recurrence are further explored. Using data collected from CGP, unsupervised machine-learning techniques were leveraged to identify 10 genomic classes in previously assigned young adult glioblastomas. The authors relate these molecular classes to current World Health Organization guidelines and reference current literature to give therapeutic and prognostic descriptions where possible.

Funder

Foundation Medicine Inc

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Reference34 articles.

1. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial;Gilbert,2013

2. Bevacizumab for newly diagnosed glioblastoma;Gilbert,2014

3. Targeted next-generation sequencing of 565 neuro-oncology patients at UCLA: a single-institution experience;Ji,2020

4. The 2021 WHO classification of tumors of the central nervous system: a summary;Louis,2021

5. The 2016 WHO classification of tumours of the central nervous system: the major points of revision;Komori,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3